TegoScience Inc. (KOSDAQ:191420)
South Korea · Delayed Price · Currency is KRW 7,580.00
+30.00 (0.40%)
At close: Sep 4, 2026
TegoScience Revenue
TegoScience had revenue of 1.97B KRW in the quarter ending June 30, 2026, with 21.92% growth. This brings the company's revenue in the last twelve months to 6.18B, down -5.15% year-over-year. In the year 2025, TegoScience had annual revenue of 5.94B, down -12.11%.
Revenue (ttm)
6.18B
Revenue Growth
-5.15%
P/S Ratio
9.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
60.69B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.94B | -818.34M | -12.11% |
| Dec 31, 2024 | 6.76B | -1.01B | -13.04% |
| Dec 31, 2023 | 7.77B | 94.02M | 1.22% |
| Dec 31, 2022 | 7.68B | -621.23M | -7.49% |
| Dec 31, 2021 | 8.30B | -489.49M | -5.57% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| Psomagen | 60.70B |
| J2KBIO | 43.90B |
| Naturalendo Tech | 22.79B |
| PanGen Biotech | 14.18B |
| ADBiotech | 12.51B |
| QuadMedicine | 7.14B |
| NovMetaPharma | 1.30B |